– USA, CA – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) today announced the appointment of Sue-Jean Lin to its Board of Directors effective June 9, 2021.
Arcutis is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions or immuno-dermatology.
“We are pleased to welcome Sue-Jean to the Arcutis Board,” said CEO, Frank Watanabe. “She brings unique and very deep digital and information technology expertise to our board, as well as extensive executive experience in the life sciences industry. With 30 years of digital, operational, financial, and leadership experience in driving higher business performance for global pharmaceutical companies, Sue-Jean will play a critical role in guiding Arcutis as we expand and advance our pipeline of novel immuno-dermatology drug candidates and prepare for our first potential commercial launch.”
The company also announced that Jonathan Silverstein has decided to step down from the Board.
“We thank Jonathan for his outstanding contributions to Arcutis,” said Board Chairman, Patrick Heron. “His leadership was instrumental in driving the continued success of the company over the past 4 years, including providing invaluable input to multiple successful private and public financings. We wish him all the best in his future endeavors, and we will deeply miss his intellect, humor, and friendship.”
About Sue-Jean Lin
Ms. Lin is SVP and Chief Information Officer at Alcon (NYSE: ALC), a global leader in eye care where she played a key role during its journey to becoming an independent, publicly-traded company. Before Alcon, she was a member of the Hill-Rom executive leadership team, serving in the capacity of SVP and CIO. Here she was instrumental in developing a new business model that enabled patient engagement and improved the effectiveness of biomedical professionals. During her career, she also served multiple roles at Allergan, including as the SVP and CIO, and as the regional Chief Financial Officer for Allergan’s Europe, Middle East, Africa, and Asia Pacific commercial operations.
“I am thrilled to join the Arcutis board at this pivotal time,” said Sue-Jean Lin. “The Company’s lead product candidate, topical roflumilast, shows strong promise as an innovative treatment for skin diseases where there is currently significant unmet need. I look forward to supporting the company’s growth trajectory with my insight and expertise, specifically in digital transformation, information technology, finance, risk management, and commercial operations.”
Ms. Lin holds a bachelor’s degree in accounting and a master’s degree in business administration from the University of Nevada, Reno.
About Arcutis
Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.
For more information: https://arcutis.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
